JP2024521329A5 - - Google Patents

Info

Publication number
JP2024521329A5
JP2024521329A5 JP2023573384A JP2023573384A JP2024521329A5 JP 2024521329 A5 JP2024521329 A5 JP 2024521329A5 JP 2023573384 A JP2023573384 A JP 2023573384A JP 2023573384 A JP2023573384 A JP 2023573384A JP 2024521329 A5 JP2024521329 A5 JP 2024521329A5
Authority
JP
Japan
Prior art keywords
approximately
seq
range
buffering agent
mtorr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023573384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024521329A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/031694 external-priority patent/WO2022256359A1/en
Publication of JP2024521329A publication Critical patent/JP2024521329A/ja
Publication of JP2024521329A5 publication Critical patent/JP2024521329A5/ja
Pending legal-status Critical Current

Links

JP2023573384A 2021-06-01 2022-06-01 凍結乾燥タンパク質製剤を製造する迅速な方法 Pending JP2024521329A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195265P 2021-06-01 2021-06-01
US63/195,265 2021-06-01
PCT/US2022/031694 WO2022256359A1 (en) 2021-06-01 2022-06-01 Accelerated method of making lyophilized protein formualtions

Publications (2)

Publication Number Publication Date
JP2024521329A JP2024521329A (ja) 2024-05-31
JP2024521329A5 true JP2024521329A5 (cg-RX-API-DMAC10.html) 2025-06-09

Family

ID=82100125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023573384A Pending JP2024521329A (ja) 2021-06-01 2022-06-01 凍結乾燥タンパク質製剤を製造する迅速な方法

Country Status (14)

Country Link
US (1) US20240368254A1 (cg-RX-API-DMAC10.html)
EP (1) EP4346778A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024521329A (cg-RX-API-DMAC10.html)
KR (1) KR20240016260A (cg-RX-API-DMAC10.html)
CN (1) CN117241787A (cg-RX-API-DMAC10.html)
AR (1) AR126044A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022285665A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023024757A2 (cg-RX-API-DMAC10.html)
CA (1) CA3217210A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003443A1 (cg-RX-API-DMAC10.html)
IL (1) IL307677A (cg-RX-API-DMAC10.html)
MX (1) MX2023014034A (cg-RX-API-DMAC10.html)
TW (1) TW202313108A (cg-RX-API-DMAC10.html)
WO (1) WO2022256359A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4553432T3 (da) 2023-11-08 2026-06-29 Bachem Holding Ag Tørrepose og tørresystem
CN122122428A (zh) 2023-11-08 2026-05-29 巴克姆股份公司 干燥袋和干燥系统

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
AU2001264946A1 (en) 2000-05-24 2001-12-03 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
HUE059339T2 (hu) * 2017-09-15 2022-11-28 Amgen Inc Eljárás terápiás fehérje liofilizált gyógyászati kiszerelésére
EP4200333A1 (en) * 2020-08-24 2023-06-28 Amgen Inc. Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine
IL299766A (en) * 2020-09-14 2023-03-01 Amgen Inc Method of making lyophilized protein formulations

Similar Documents

Publication Publication Date Title
CN102712677B (zh) 脂肽组合物和相关方法
EP2458990B1 (en) Methods for producing high concentration lyophilized pharmaceutical formulations
US10286037B2 (en) Methods of producing lyophilized polypeptide composition formulations comprising volatile additives
US8795686B2 (en) Stable, dried rotavirus vaccine, compositions and process for preparation thereof
JP2021521119A5 (cg-RX-API-DMAC10.html)
US12251474B2 (en) Process for lyophilized pharmaceutical formulations of a therapeutic protein
EP0065905A1 (fr) Perfectionnements apportés aux agents de stabilisation de virus vivants pour la préparation de vaccins, et vaccins stabilisés contenant lesdits agents de stabilisation
US11713922B2 (en) Target residual moisture content for lyophilized drug product
JP3105494B2 (ja) 蛋白質を安定化するための改良された方法
JP2023539476A5 (cg-RX-API-DMAC10.html)
JP2023538669A5 (cg-RX-API-DMAC10.html)
EP3915586A1 (fr) Excipient stabilisant pour vaccin a virus entiers inactives
CA2554018A1 (en) Lyophilization method to improve excipient crystallization
JP2025016453A5 (cg-RX-API-DMAC10.html)
US20090208509A1 (en) Pharmaceutical formulation of an antibody against IL-1R
RU2014151424A (ru) Термостабильные составы вакцины
JP7218305B2 (ja) 凍結乾燥製剤の製造方法
JP7085482B2 (ja) スタフィロコッカス感染症のための凍結乾燥製剤を製造する方法
WO2020003139A2 (en) Stable lyophilized dosage form of protein
JP2023524444A5 (cg-RX-API-DMAC10.html)
JP2023524445A5 (cg-RX-API-DMAC10.html)
CN120789003A (zh) 一种蛋白冻干制剂与高浓度蛋白制剂的制备方法
JP2024523443A5 (cg-RX-API-DMAC10.html)
US20250312436A1 (en) Stabilization of virus-based therapeutic agent
Wang Formulation characterization